Crosslinked Polymer Hydrogel Drug Delivery with Controlled Release Profiles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current biocompatible crosslinked polymers for drug delivery lack efficient mechanisms for varying drug release profiles, often requiring high systemic concentrations that can cause adverse side effects and inefficient release mechanisms.
Innovation Solution
Development of biocompatible crosslinked polymer hydrogels with multiple drug release profiles, achieved by incorporating drugs without binding, through degradable pendant linkages, and into the polymer backbone or non-degradable pendant linkages, utilizing electrophilic-nucleophilic reactions and biodegradable linkages, allowing for controlled release of single or multiple drugs at different times.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high systemic concentrations of drugs are administered to achieve therapeutic effects, then the desired therapeutic effect is improved, but adverse side effects increase
Solution Approach 1:
The patent segments the drug delivery system into multiple compartments or formulations, each designed to release drugs at different rates and locations. This allows therapeutic agents to be delivered in a controlled manner rather than as a single high-concentration systemic dose, reducing peak concentrations and associated side effects while maintaining therapeutic efficacy through targeted delivery.
Solution Approach 2:
The patent employs preliminary action by pre-formulating drugs in controlled-release formulations or targeting systems before administration. This allows the drug to be delivered gradually or directed to specific tissues in advance, preventing the need for high immediate systemic concentrations that cause adverse effects while ensuring therapeutic levels are achieved where needed.
2Duration of action of moving object
If extended release forms of medicaments are used to prolong drug effects, then the duration of action is improved, but the release mechanism becomes inefficient or complex
Solution Approach 1:
The patent utilizes parameter changes by modifying the physical or chemical properties of the drug formulation, such as particle size, solubility, or association with carriers, to achieve extended release without complex mechanisms. By changing these parameters, the drug naturally releases over an extended period through passive diffusion, degradation, or other simple processes, avoiding the need for sophisticated release mechanisms.
3Reliability
If multiple drugs are delivered simultaneously at high concentrations, then comprehensive treatment is improved, but adverse side effects and toxicity increase
Solution Approach 1:
The patent segments the delivery of multiple drugs into separate formulations or sequential release profiles. Instead of delivering all drugs simultaneously at high concentrations, each drug is formulated to release at appropriate times and locations, achieving comprehensive treatment while avoiding the cumulative toxicity that would result from simultaneous high-concentration delivery of multiple agents.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables precise and controlled drug release profiles from 0 to 180 days, reducing adverse side effects and improving the efficiency of drug delivery by varying the release times of single or multiple drugs, depending on the application.
Implementation Method 1
the at least one drug having said second drug release profile corresponding to a second drug release profile of from about 0 days to about 30 days is incorporated into the crosslinked polymer hydrogel by covalent binding through degradable pendant linkages
Data Source
AI summary
Drug delivery devices are provided herein including crosslinked polymeric compositions. The devices may, in embodiments, possess at least two drug release profiles, in embodiments at least three drug release profiles.